Trend of the Incidence Rate of Kidney and Ureter Cancer in Iran from 2004 to 2016

IF 0.4 Q4 ONCOLOGY

International Journal of Cancer Management Pub Date : 2024-01-02 DOI:10.5812/ijcm-140329

Saeed Erfanpoor, Paria Dehesh, Jalil Hasani, Fereshteh Davoodi, M. Akbari, M. Hadizadeh, K. Etemad

{"title":"Trend of the Incidence Rate of Kidney and Ureter Cancer in Iran from 2004 to 2016","authors":"Saeed Erfanpoor, Paria Dehesh, Jalil Hasani, Fereshteh Davoodi, M. Akbari, M. Hadizadeh, K. Etemad","doi":"10.5812/ijcm-140329","DOIUrl":null,"url":null,"abstract":"Background: Kidney and ureter cancers are two of the most prevalent urological cancers among Iranians. However, studies on the epidemiology and incidence of these cancers are primarily regional and focus on a specific period. Objectives: The present study investigated the trend of the incidence rate of kidney and ureter cancer in Iran from 2004 to 2016. Methods: In this study, information on kidney and ureter cancer cases in Iran from 2004 to 2016 was extracted from the Iranian National Cancer Registry (INCR). Crude and age-specific incidence rates (ASIR) were calculated, and the age-standardized rate (ASR) was measured, using the World Health Organization (WHO) standard population. The Joinpoint software program 4.9.0.1 was used to calculate the annual percent changes (APC) in the trend of the incidence rate of kidney and ureter cancers by age group, regional centers, and tumor grades across a 13-year period. Results: During the study period, 19 659 incidences of ureter and kidney cancer occurred in Iran. The crude and ASR of kidney cancer increased from 0.98 and 1.33 per 100 000 population in 2004 to 3.1 and 3.5 per 100 000 population in 2016, respectively. In addition, the crude and ASR of ureter cancer increased from 0.04 and 0.05 per 100 000 population in 2004 to 0.9 and 1.1 per 100 000 population in 2016, respectively. The national ASR of kidney cancer APC was 22.2% (P > 0.05) from 2004 to 2006 and 4.8% (P < 0.05) from 2006 to 2016, respectively. The national ASR of ureter cancer APC was 290.8% (P < 0.05) from 2004 to 2006 and 7.5% (P < 0.05) from 2006 to 2016. Conclusions: According to the results of this study, the incidence rate of kidney and ureter cancer increased over 13 years in Iran. Hence, the implementation of epidemiological studies in various regions and provinces is crucial for gaining a comprehensive and precise understanding of the underlying causes of kidney and ureter cancer incidence.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"61 15","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-140329","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Kidney and ureter cancers are two of the most prevalent urological cancers among Iranians. However, studies on the epidemiology and incidence of these cancers are primarily regional and focus on a specific period. Objectives: The present study investigated the trend of the incidence rate of kidney and ureter cancer in Iran from 2004 to 2016. Methods: In this study, information on kidney and ureter cancer cases in Iran from 2004 to 2016 was extracted from the Iranian National Cancer Registry (INCR). Crude and age-specific incidence rates (ASIR) were calculated, and the age-standardized rate (ASR) was measured, using the World Health Organization (WHO) standard population. The Joinpoint software program 4.9.0.1 was used to calculate the annual percent changes (APC) in the trend of the incidence rate of kidney and ureter cancers by age group, regional centers, and tumor grades across a 13-year period. Results: During the study period, 19 659 incidences of ureter and kidney cancer occurred in Iran. The crude and ASR of kidney cancer increased from 0.98 and 1.33 per 100 000 population in 2004 to 3.1 and 3.5 per 100 000 population in 2016, respectively. In addition, the crude and ASR of ureter cancer increased from 0.04 and 0.05 per 100 000 population in 2004 to 0.9 and 1.1 per 100 000 population in 2016, respectively. The national ASR of kidney cancer APC was 22.2% (P > 0.05) from 2004 to 2006 and 4.8% (P < 0.05) from 2006 to 2016, respectively. The national ASR of ureter cancer APC was 290.8% (P < 0.05) from 2004 to 2006 and 7.5% (P < 0.05) from 2006 to 2016. Conclusions: According to the results of this study, the incidence rate of kidney and ureter cancer increased over 13 years in Iran. Hence, the implementation of epidemiological studies in various regions and provinces is crucial for gaining a comprehensive and precise understanding of the underlying causes of kidney and ureter cancer incidence.

查看原文本刊更多论文

2004 至 2016 年伊朗肾癌和输尿管癌发病率趋势

背景：肾癌和输尿管癌是伊朗人最常见的两种泌尿系统癌症。然而，对这两种癌症的流行病学和发病率的研究主要是区域性的，而且主要集中在特定时期。研究目的本研究调查了 2004 年至 2016 年伊朗肾癌和输尿管癌发病率的变化趋势。研究方法本研究从伊朗国家癌症登记处（INCR）提取了 2004 年至 2016 年伊朗肾癌和输尿管癌病例的信息。采用世界卫生组织（WHO）标准人群计算粗发病率和年龄特异性发病率（ASIR），并测量年龄标准化发病率（ASR）。使用 Joinpoint 软件程序 4.9.0.1 计算了 13 年间按年龄组、地区中心和肿瘤等级划分的肾癌和输尿管癌发病率趋势的年度百分比变化 (APC)。研究结果在研究期间，伊朗共发生 19 659 例输尿管癌和肾癌。肾癌的粗发病率和 ASR 分别从 2004 年的每 10 万人 0.98 例和 1.33 例增加到 2016 年的每 10 万人 3.1 例和 3.5 例。此外，输尿管癌的粗略死亡率和 ASR 分别从 2004 年的每 10 万人 0.04 例和 0.05 例增至 2016 年的每 10 万人 0.9 例和 1.1 例。2004年至2006年，全国肾癌APC的ASR分别为22.2%（P > 0.05），2006年至2016年分别为4.8%（P < 0.05）。2004年至2006年，全国输尿管癌APC的ASR为290.8%（P < 0.05），2006年至2016年为7.5%（P < 0.05）。结论：根据这项研究的结果，伊朗肾癌和输尿管癌的发病率在 13 年间有所上升。因此，在不同地区和省份开展流行病学研究对于全面、准确地了解肾癌和输尿管癌发病的根本原因至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Cancer Management ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.